Mirtazapine (Remeron) Can Be Used During First Trimester Pregnancy, Though Ideally Avoided When Possible
Based on the most recent and highest-quality evidence, mirtazapine does not appear to increase the risk of major congenital malformations when used during the first trimester of pregnancy. The 2022 Danish nationwide cohort study—the largest and most rigorous study to date—found no association between first-trimester mirtazapine exposure and major congenital malformations, spontaneous abortion, stillbirth, or neonatal death 1.
Evidence Quality and Strength
The evidence base for mirtazapine safety in pregnancy has evolved significantly:
Most recent large-scale study (2022): A propensity score-matched Danish cohort of 4,475 pregnancies found no increased risk of major malformations (3.5% exposed vs 4.3% unexposed; OR=0.81,95% CI 0.55-1.20) 1. This study specifically addressed first-trimester exposure and used rigorous methodology to control for confounding.
Systematic review (2025): Concluded that most studies show outcomes in mirtazapine-exposed pregnancies comparable to controls, though results on congenital malformations were conflicting and overall quality of evidence was low 2.
Earlier prospective studies: A 2015 multicenter European study of 357 pregnancies showed no significant difference in major birth defects between mirtazapine and SSRI-exposed groups (4.5% vs 4.2%) 3. A 2006 prospective study of 104 pregnancies found 2 major malformations among 77 live births, within baseline population rates 4.
Clinical Decision-Making Algorithm
When depression requires treatment in first trimester:
- Assess severity and necessity: If the patient has moderate-to-severe depression requiring pharmacologic treatment, mirtazapine is a reasonable option
- Consider alternatives first: SSRIs have more extensive safety data in pregnancy, though mirtazapine appears similarly safe 3
- If already on mirtazapine: The 2022 Danish study provides reassurance that continuing therapy does not increase fetal risk 1
- Dosing: Use the lowest effective dose, as recommended by general pregnancy medication principles 5
Important Caveats and Risks
Neonatal Adaptation Syndrome (PNAS):
- Occurs in approximately 25.9% of infants exposed to mirtazapine in the third trimester 6
- This rate is similar to other antidepressants
- Symptoms are typically self-limited
- Protective factor: Breastfeeding significantly reduces PNAS incidence (18.6% vs 54.5% in non-breastfed infants, p=0.024) 6
Spontaneous Abortion:
- Some studies show higher rates of spontaneous abortion with antidepressants generally (19% mirtazapine vs 11% non-teratogen controls), though not statistically significant 4
- The 2022 Danish study found no increased risk (HR=1.04,95% CI 0.91-1.20) 1
- This likely reflects underlying depression severity rather than medication effect
Preterm Birth:
- One study found higher preterm birth rates (10% mirtazapine vs 2% controls, p=0.04) 4, though this was not confirmed in the larger 2022 study 1
FDA Labeling and Regulatory Context
The FDA label for Remeron advises patients to notify their physician if they become pregnant and mentions a pregnancy exposure registry 7. The label does not contraindicate use in pregnancy but recommends physician notification, consistent with a risk-benefit approach.
Practical Recommendations
If prescribing mirtazapine in first trimester:
- Document discussion of risks and benefits
- Use 15 mg as starting dose (typical antidepressant dose)
- Monitor for treatment response
- Plan for potential PNAS if continuing into third trimester
- Encourage breastfeeding postpartum to reduce PNAS risk 6
If patient discovers pregnancy while on mirtazapine:
- Do not abruptly discontinue due to risk of withdrawal and depression relapse
- Reassure based on 2022 Danish data showing no increased malformation risk 1
- Consider psychiatric consultation if uncertain about continuing
Comparison to Other Antidepressants
The evidence suggests mirtazapine safety is comparable to SSRIs in pregnancy 3. While SSRIs have more extensive data, the 2022 Danish study provides strong reassurance for mirtazapine specifically 1. The general principle from cardiovascular guidelines that "antiarrhythmic drugs should be avoided in the first trimester, when risk of congenital malformations is greatest" 5 applies less stringently to antidepressants, where untreated maternal depression carries its own substantial risks.
The key clinical message: Mirtazapine can be used when clinically indicated during first trimester pregnancy, with the most recent high-quality evidence showing no increased risk of major malformations. The decision should weigh the risks of untreated maternal depression against theoretical medication risks, with current data favoring treatment when needed.